Monday, April 14, 2025
Home 2024 Watch List

2024 Watch List

    Latest

    Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.

    2024 Watch List Editor / Curator -
    Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List...

    Ardelyx (ARDX), Raymond James up Price Target, Citigroup Joins the Party.

    2024 Watch List Editor / Curator -
    Wall Street Cozy's up to Ardelyx After New Guidance. On January 8th, Mike Raab, President and Chief Executive...

    Is David Dodd on to his Next Billion Dollar Payday for Shareholders?

    2024 Watch List Editor / Curator -
    Huge News: Gedeptin® Therapy Demonstrated Safety, Stabilization and Shrinkage of Treated Tumors. GeoVax (GOVX) Completes Patient...

    Two That Doubled and Now Look Ready to Break Out.. and a Third That...

    2024 Watch List Editor / Curator -
    We are up 234% in Ardelyx (ARDX) $5.23 since adding it to Watch List a year ago and up 71% in Cardiol...

    COMPASS Pathways (CMPS) Announces Up to $285 Million Private Placement

    2024 Watch List Editor / Curator -
    Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to...

    Latest article

    Adding Allarity (ALLR) $0.75, to Watch List

    Featured Editor / Curator -

    Bavarian Nordic (BVNRY) Freeze Dries its MPOX Vaccine!

    2025 Watch List Editor / Curator -
    This is Big News, Honestly. We Are Adding to 2025 Watch List @ $7.36. We last added Bavarian to...

    Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.’s ‘Misinformation And Lies’ (IBD)

    All News Editor / Curator -
    Sorting Through the Wreckage! Full post on Investor's Business Daily. Biotech stocks took a beating Monday...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.